Prediction of response to definitive chemoradiotherapy in esophageal cancer using positron emission tomography

Anticancer Research

Volumn 27, Issue 4 C, 2007, Pages 2627-2633

  Kato, Hiroyuki ^a   Fukuchi, Minoru ^a   Miyazaki, Tatsuya ^a   Nakajima, Masanobu ^a   Tanaka, Naritaka ^a   Inose, Takanori ^a   Kimura, Hitoshi ^a   Faried, Ahmad ^a   Saito, Kana ^a   Sohda, Makoto ^a   Fukai, Yasuyuki ^a   Masuda, Norihiro ^a   Manda, Ryokuhei ^a   Ojima, Hitoshi ^a   Tsukada, Katsuhiko ^a   Oriuchi, Noboru ^a   Endo, Keigo ^a   Nonaka, Tetsuo ^a   Shioya, Mariko ^a   Ishikawa, Hitoshi ^a   Sakurai, Hideyuki ^a   Nakano, Takashi ^a   Kuwano, Hiroyuki ^a   more..

^a GUNMA UNIVERSITY   (Japan)

Author keywords

18F fluorodeoxyglucose; Chemoradiotherapy; CRT; Esophageal cancer; FDG; PET; Positron emission tomography; Response to therapy

Indexed keywords

DOCETAXEL; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; NEDAPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; CONTINUOUS INFUSION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG UPTAKE; ESOPHAGUS CANCER; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MALE; MULTIVARIATE ANALYSIS; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TREATMENT RESPONSE;

AGED; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES;

EID: 34547767719     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Bar-Shalom R, Valdivia AY and Blaufox MD: PET imaging in oncology. Semin Nucl Med 30: 150-185, 2000.
2. Bares R, Klever P, Hauptmann S, Hellwig D, Fass J, Cremerius U, Schumpelick V, Mittermayer C and Bull U: F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology 192: 79-86, 1994.
3. Inoue T, Kim EE, Komaki R, Wong FC, Bassa P, Wong WH, Yang DJ, Endo K and Podoloff DA: Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med 36: 788-793, 1995.
4. Ahuja V, Coleman RE, Herndon J and Patz EF Jr: The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 83: 918-924, 1998.
5. Coleman RE. PET in lung cancer. J Nucl Med 40: 814-820, 1999.
6. Block MI, Patterson GA, Sundaresan RS, Bailey MS, Flanagan FL, Dehdashti F, Siegel BA and Cooper JD: Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thorac Surg 64: 770-776, 1997.
7. Luketich JD, Schauer PR, Meltzer CC, Landreneau RJ, Urso GK, Townsend DW, Ferson PF, Keenan RJ and Belani CP: Role of positron emission tomography in staging esophageal cancer. Ann Thorac Surg 64: 765-769, 1997.
8. 18F- fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 168: 417-424, 1997
9. Kole AC, Plukker JT, Nieweg OE and Vaalburg W: Positron emission tomography for staging of oesophageal and gastroesophageal malignancy. Br J Cancer 78: 521-527, 1998.
10. Rankin SC, Taylor H, Cook GJ and Mason R: Computed tomography and positron emission tomography in the preoperative staging of oesophageal carcinoma. Clin Radiol 53: 659-665, 1998.
11. Kobori O, Kirihara Y, Kosaka N and Hara T: Positron emission tomography of esophageal carcinoma using (11)C-choline and (18)F-fluorodeoxyglucose: a novel method of preoperative lymph node staging. Cancer 86: 1638-1648, 1999.
12. Yeung HW, Macapinlac HA, Mazumdar M, Bains M, Finn RD and Larson SM: FDG-PET in esophageal cancer. Incremental value over computed tomography. Clin Positron Imaging 2: 255-260, 1999.
13. 18F-FDG positron emission tomography in gastric and oesophageal carcinoma. Br J Radiol 72: 525-529, 1999.
14. Skehan SJ, Brown AL, Thompson M, Young JE, Coates G and Nahmias C: Imaging features of primary and recurrent esophageal cancer at FDG-PET. Radiographics 20: 713-723, 2000.
15. Flamen P, Lerut A, Van Cutsem E, Cambier JP, Maes A, De Wever W, Peeters M, De Leyn P, Van Raemdonck D and Mortelmans L: The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer. J Thorac Cardiovasc Surg 120: 1085-1092, 2000.
16. Brucher BL, Weber W, Bauer M, Fink U, Avril N, Stein HJ, Werner M, Zimmerman F, Siewert JR and Schwaiger M: Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 233: 300-339, 2001.
17. Flamen P, Van Cutsem E, Lerut A, Cambier JP, Haustermans K, Bormans G, De Leyn P, Van Raemdonck D, De Wever W, Ectors N, Maes A and Mortelmans L: Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 13: 361-368, 2002.
18. Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, Meisetschlager G, Busch R, Siewert JR, Schwaiger M and Fink U: Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19: 3058-3065, 2001.
19. Kato H, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Masuda N, Fukuchi M, Manda R, Tsukada K, Oriuchi N and Endo K: Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer. Am J Surg 184: 279-283, 2002.
20. Kato H, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Ojima H, Tsukada K, Oriuchi N, Inoue T and Endo K: Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer 94: 921-928, 2002.
21. Kato H, Miyazaki T, Nakajima M, Takita J, Kimura H, Faried A, Sohda M, Fukai Y, Masuda N, Fukuchi M, Manda R, Ojima H, Tsukada K, Kuwano H, Oriuchi N and Endo K: The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer 103: 148-156, 2005.
22. Kato H, Fukuchi M, Miyazaki T, Nakajima M, Kimura H, Faried A, Sohda M, Fukai Y, Masuda N, Manda R, Ojima H, Tsukada K, Oriuchi N, Endo K and Kuwano H: Positron emission tomography in esophageal cancer. Esophagus 2: 111-121, 2005.
23. Pisani P, Parkin DM and Ferlay J: Estimates of the worldwide mortality from eighteen major cancers in 1985: implications for prevention and projections of future burden. Int J Cancer 55: 891-903, 1993.
24. Kato H, Fukuchi M, Miyazaki T, Nakajima M, Kimura H, Faried A, Sohda M, Fukai Y, Masuda N, Manda R, Ojima H, Tsukada K and Kuwano H: Classification of recurrent esophageal cancer after radical esophagectomy with two- or three-field lymphadenectomy. Anticancer Res 25: 3461-3467, 2005.
25. Ohtsu A: Chemoradiotherapy for esophageal cancer: current status and perspectives. Int J Clin Oncol 9: 444-450, 2004.
26. Sobin LH and Wittekind C (edi.). TNM Classification of Malignant Tumors. 6th ed. New York: John Wiley & Sons, 2002.
27. Japanese Society for Esophageal Diseases. Guidelines for the clinical and pathological studies on carcinoma of the esophagus. The 9th edition. Tokyo: Kanehara, 1999.
28. 18F-FDG-PET in esophageal carcinoma. Eur J Surg Oncol 30: 544-550, 2004.
29. Swisher SG, Maish M, Erasmus JJ, Correa AM, Ajani JA, Bresalier R, Komaki R, Macapinlac H, Munden RF, Putnam JB, Rice D, Smythe WR, Vaporciyan AA, Walsh GL, Wu TT and Roth JA: Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 78: 1152-1160, 2004.
30. Wieder HA, Brucher BL, Zimmermann F, Becker K, Lordick F, Beer A, Schwaiger M, Fink U, Siewert JR, Stein HJ and Weber WA: Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 22: 900-908, 2004.
31. Downey RJ, Akhurst T, Ilson D, Ginsberg R, Bains MS, Gonen M, Koong H, Gollub M, Minsky BD, Zakowski M, Turnbull A, Larson SM and Rusch V: Whole body 18FDG PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 21: 428-432, 2003.
32. Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, Cox JD, Komaki RR, Hong D, Lee HK, Putnam JB Jr, Rice DC, Smythe WR, Thai L, Vaporciyan AA, Walsh GL, Wu TT and Roth JA: 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 101: 1776-1785, 2004.
33. Couper GW, McAteer D, Wallis F, Norton M, Welch A, Nicolson M and Park KG: Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer. Br J Surg 85: 1403-1406, 1998.
34. Nakamura R, Obara T and Katsuragawa S: Failure in presumption of residual disease by quantification of FDG uptake in esophageal squamous cell carcinoma immediately after RT. Radiat Med 20: 181-186, 2002.
35. Kostakoglu L and Goldsmith SJ: PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. J Nucl Med 45: 56-68, 2004.
36. Westerterp M, van Westreenen HL, Reitsma JB, Hoekstra OS, Stoker J, Fockens P, Jager PL, Van Eck-Smit BL, Plukker JT, van Lanschot JJ and Sloof GW: Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy - systematic review. Radiology 236: 841-851, 2005.